INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS
metrics 2024
Pioneering Research in Biological Markers
Introduction
Welcome to the International Journal of Biological Markers, a distinguished publication under SAGE Publications Ltd that has been a vital resource in the fields of Cancer Research, Clinical Biochemistry, Oncology, and Pathology and Forensic Medicine since its inception in 1986. With a commitment to disseminating high-quality research, the journal enjoys a robust impact highlighted by its Q2 and Q3 rankings across multiple categories in 2023, as evidenced by its Scopus rankings placing it in respectable percentiles. Based in Italy, this journal serves a global audience of researchers, clinicians, and students eager to keep abreast of the latest discoveries involving biological markers and their applications in medicine. Emphasizing rigorous peer review and scholarly integrity, the International Journal of Biological Markers plays a crucial role in advancing knowledge that can significantly impact clinical practices and enhance patient care.
Metrics 2024
Metrics History
Rank 2024
Scopus
IF (Web Of Science)
JCI (Web Of Science)
Quartile History
Similar Journals
Journal of Cancer Metastasis and Treatment
Exploring breakthroughs in metastasis and therapy.Journal of Cancer Metastasis and Treatment, published by OAE PUBLISHING INC, stands as a vital resource in the field of oncology, focusing on advancements and research pertaining to cancer metastasis and treatment methodologies. With an ISSN of 2394-4722 and an E-ISSN of 2454-2857, this journal aims to serve as a comprehensive platform for sharing innovative research, critical analyses, and novel findings from 2019 through 2024. As indexed in Scopus, it holds a notable Q3 ranking within its category, positioned at 240/404 and within the 40th percentile, thus reflecting its growing significance in the scientific community. Though currently not open access, the journal aspires to improve accessibility to pivotal oncology research, making it an essential tool for researchers, clinicians, and students keen on unraveling the complexities of cancer treatment and metastasis. Its commitment to promoting high-quality studies plays a crucial role in the ongoing quest to enhance patient care and outcomes in cancer treatment.
ACTA HISTOCHEMICA
Illuminating Cell Structures Through Rigorous Histochemical StudyACTA HISTOCHEMICA, a prestigious journal published by Elsevier GmbH, is dedicated to advancing the field of histochemistry and its applications within cell biology and medicine. With an ISSN of 0065-1281 and an E-ISSN of 1618-0372, the journal provides a critical platform for the dissemination of high-quality research findings and reviews, integral for both emerging and established scholars. Since its inception in 1954 and continuing through to 2024, ACTA HISTOCHEMICA has maintained a strong commitment to publishing significant advancements in histology and cell biology, as evidenced by its categorization in Q3 for Cell Biology and Histology, as well as Q2 in miscellaneous medicine for the year 2023. The journal ranks favorably in Scopus, holding the 27th rank in Histology and a 200th rank in Cell Biology, highlighting its importance to the academic community. With its headquarters in Munich, Germany, ACTA HISTOCHEMICA continues to attract contributions from global researchers, fostering an international dialogue essential for the growth of knowledge in histochemistry and related disciplines.
CLINICAL & EXPERIMENTAL METASTASIS
Illuminating Pathways in Cancer ProgressionCLINICAL & EXPERIMENTAL METASTASIS is a highly regarded academic journal dedicated to the study of cancer metastasis, published by Springer. With an ISSN of 0262-0898 and an E-ISSN of 1573-7276, this journal serves as a pivotal resource for researchers and professionals dedicated to understanding the complexities of metastatic disease. Based in the Netherlands, it boasts an impressive impact factor, solidifying its position in two major quartiles: Q2 in Cancer Research and Q1 in both Medicine (Miscellaneous) and Oncology for 2023. The journal not only ranks among the top tier in Medicine Oncology—84th out of 404—but also excels in Biochemistry, Genetics and Molecular Biology in Cancer Research, ranking 75th out of 230. With coverage spanning from 1983 to 2024, CLINICAL & EXPERIMENTAL METASTASIS presents cutting-edge research, reviews, and clinical studies that drive the field forward. This journal is essential for anyone looking to deepen their understanding of cancer metastasis and its underlying mechanisms.
Annals of Diagnostic Pathology
Unveiling New Horizons in Pathologic Research.Annals of Diagnostic Pathology, published by Elsevier Science Inc, is a pivotal journal in the field of diagnostic pathology that has significantly contributed to the advancement of medical science since its inception in 1997. With an ISSN of 1092-9134 and E-ISSN of 1532-8198, this esteemed journal is positioned within the Q2 category in both Medicine (miscellaneous) and Pathology and Forensic Medicine, reflecting its high-quality research contributions, showcased by its ranking at #73 out of 208 in Scopus for the latter category. The journal's scope encompasses various aspects of diagnostic pathology, from innovative techniques to critical reviews of pathologic findings, making it an essential resource for researchers, medical professionals, and students dedicated to enhancing diagnostic accuracy and patient care. Although it does not currently offer open access options, its wide readership and impactful publications continue to influence clinical practices and research agendas. With a convergence period extending to 2024, Annals of Diagnostic Pathology remains a leading platform for disseminating valuable knowledge in this dynamic field.
Tumori Journal
Transforming Cancer Research into Clinical Practice.Tumori Journal is a distinguished publication in the field of oncology, dedicated to advancing the understanding and treatment of cancer since its inception in 1946. Published by SAGE Publications Ltd, this Italian journal serves as a pivotal platform for researchers, clinicians, and academicians to disseminate cutting-edge findings in cancer research and related areas of medicine. With an impressive record of contributions spanning multiple decades, Tumori Journal aims to foster collaboration and dialogue among professionals in the oncology community. Although classified in the Q4 category for Cancer Research and the Q3 category for both Medicine (miscellaneous) and Oncology as of 2023, the journal continues to draw interest with its rigorous peer-review process and commitment to quality. Researchers are encouraged to explore innovative methodologies and share impactful clinical insights through the journal, which also ranks within the top tiers of Scopus metrics for oncology and cancer research domains. With a growing emphasis on accessible research, Tumori Journal remains an essential resource in the continuous fight against cancer.
Oncogenesis
Connecting the dots in cancer biology and treatment.Oncogenesis is a prestigious open access journal, published by SpringerNature, dedicated to advancing our understanding of cancer biology and molecular mechanisms of oncogenesis. Since its inception in 2012, this journal has quickly established itself as a leading platform for innovative research, being ranked in the Q1 quartile in both Cancer Research and Molecular Biology categories for 2023. With an admirable impact factor that reflects its exceptional quality, Oncogenesis is indexed in Scopus, holding notable rankings in both Molecular Biology and Cancer Research, placing in the 87th and 83rd percentile respectively. The journal not only facilitates the dissemination of groundbreaking research but also encourages collaboration among scientists and healthcare professionals across the globe. By offering open access to its articles, Oncogenesis ensures that vital findings reach a diverse audience, fostering a deeper dialogue and understanding in the fight against cancer. Based in the United States but with a global reach, the journal remains committed to publishing high-impact studies that contribute to the advancement of knowledge in the realms of oncology, biochemistry, and genetics.
IN VIVO
Elevating biochemistry and molecular biology to new heights.IN VIVO is a prestigious academic journal published by the International Institute of Anticancer Research, dedicated to advancing the fields of biochemistry, genetics, molecular biology, cancer research, and pharmacology. With its ISSN 0258-851X and E-ISSN 1791-7549, this journal has been a key contributor to innovative research since its inception in 1987, providing a crucial platform for the dissemination of significant findings in its scope. With an impressive impact reflected in its quartile rankings (Q2 in Biochemistry, Genetics and Molecular Biology and Medicine; Q3 in Cancer Research and Pharmacology), IN VIVO reaches a global audience comprising researchers, health professionals, and students. Although it operates on a subscription basis, the journal’s commitment to scientific excellence and rigorous peer review ensures that all published works maintain high quality and relevance. Notably positioned in Scopus ranks within the 36th to 59th percentiles across various categories, IN VIVO continues to be a vital resource for cutting-edge research and developments, solidifying its importance within the scientific community.
MOLECULAR IMAGING AND BIOLOGY
Illuminating Innovations in Molecular ImagingWelcome to MOLECULAR IMAGING AND BIOLOGY, an esteemed journal published by SPRINGER that delves into the rapidly advancing fields of molecular imaging and its applications in biology, with a strong emphasis on cancer research, oncology, and radiology. With ISSN 1536-1632 and E-ISSN 1860-2002, this journal has established itself as a prominent platform for disseminating insightful research and innovative methodologies since its inception in 2002. As of 2023, it holds commendable rankings in notable categories—Q3 in Cancer Research, Q2 in Oncology, and Q2 in Radiology, Nuclear Medicine, and Imaging—illustrating its impact and relevance in these disciplines. Furthermore, with impressive Scopus rankings placing it in the top quartile of journals within its categories, it serves as an essential resource for researchers, professionals, and students seeking to stay informed about the latest developments in molecular imaging technologies and biological applications. While currently not an Open Access journal, the rigorous peer-review process ensures high-quality and impactful contributions to the field, making it a valuable addition to any academic library.
Malaysian Journal of Pathology
Unveiling the intricacies of pathology since 1979.Malaysian Journal of Pathology, published by the MALAYSIAN JOURNAL PATHOLOGY, stands as a pivotal resource in the fields of pathology and medicine, contributing rich insights since its inception in 1979. This peer-reviewed journal, based in Malaysia, is dedicated to disseminating original research, review articles, and case studies that advance the understanding of disease mechanisms and diagnostics. With a current impact factor reflecting its ranked positioning—Q4 in Cell Biology, Q4 in Histology, and Q3 in both Miscellaneous Medicine and Pathology & Forensic Medicine—this journal serves as an essential platform for researchers, clinicians, and students alike. Although it operates without open access, its scholarly rigor and contributions are well recognized, holding ranks such as #84 in Pathology and Forensic Medicine according to Scopus. The Malaysian Journal of Pathology is committed to fostering innovation and excellence in medical research, making it an invaluable tool for professionals seeking to stay abreast of significant advancements in the pathology domain.
South Asian Journal of Cancer
Transforming cancer treatment through regional insights.South Asian Journal of Cancer, published by GEORG THIEME VERLAG KG, is a pivotal platform for research in the fields of oncology and cancer research. Established in 2012 and operating under an Open Access model, this journal aims to disseminate high-quality, peer-reviewed articles that address crucial developments in cancer treatment, prevention, and research, particularly within the South Asian context. Despite its young history, the journal has been positioned within the Q4 quartile for both Cancer Research and Oncology, and while current Scopus rankings indicate it resides in the lower percentiles, its commitment to amplifying regional voices and research is invaluable. With its headquarters in Stuttgart, Germany, and a global readership, South Asian Journal of Cancer is dedicated to enhancing collaboration among researchers, healthcare professionals, and students, fostering a space for innovative ideas and advancements in cancer care as we progress through to 2024.